
What is claimed is:


1. A process for the preparation of a compound having the Formula **I:**



I


or a pharmaceutically acceptable salt thereof, which comprises:

(a) coupling a compound of formula **II**



II


or a salt thereof, in which P^1 represents a hydrogen atom or a hydroxyl protecting group, with a compound of formula **III**



III

in which Z represents a leaving group, or the corresponding isocyanate; or


(b) reducing a compound of formula **IV**



IV

wherein R^e represents a hydrogen atom of a residue of an alcohol;followed by removing any protecting group and, if desired, forming a pharmaceutically acceptable salt.


2. A pharmaceutical composition, comprising a compound having the Formula **I:**



I

or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier or diluent.

3. A compound of formula II



II


or a salt thereof, in which P^1 represents a hydrogen atom or a hydroxyl protecting group.

4. The use of a compound according to claim 11 in the manufacture of a medicament for the treatment of a kinase-mediated condition in a mammal, wherein said kinase-mediated condition is inflammatory disease, autoimmune disease, destructive bone disorder, proliferative disorder, infectious disease, viral disease, or neurodegenerative disease.

5 Use as claimed in claim 4, wherein the prodrug is 2-(5-(2-((3-(3-*tert*-butyl-1-*p*-tolyl-1*H*-pyrazol-5-yl)ureido)methyl)-4-fluorophenoxy)-1*H*-indazol-1-yl)ethyl dihydrogenphosphate, or a pharmaceutically acceptable salt thereof.

6. 2-(5-(2-((3-(3-*Tert*-butyl-1-*p*-tolyl-1*H*-pyrazol-5-yl)ureido)methyl)-4-fluorophenoxy)-1*H*-indazol-1-yl)ethyl dihydrogenphosphate, or a pharmaceutically acceptable salt thereof.

7. A process for the preparation of a compound as defined in claim 6, which comprises phosphorylating a compound having the Formula **I:**



I


or a pharmaceutically acceptable salt thereof.

8. A pharmaceutical composition, comprising a compound of claim 6 and a pharmaceutically acceptable carrier or diluent.

9. The process according to claim 1, wherein Z is an aryloxy group optionally substituted with one or more groups selected from F, Cl, Br, and NO_2.

10. The process of claim 1, wherein said compound of formula (II) has been prepared by the method comprising:


(i) reducing a compound of formula (V)



(V)

in which P^2 represents hydrogen or a hydroxyl protecting group, under catalytic hydrogenation conditions or in the presence of nickel boride.

11. A compound having the Formula I in the form of a prodrug:




I

or a pharmaceutically acceptable salt thereof.

CLAIMS

1. The compound having the Formula **I:**




I

or a pharmaceutically acceptable salt thereof.


2. A process for the preparation of a compound as defined in claim 1, which comprises:

(a) coupling a compound of formula **II**



II


or a salt thereof, in which P^1 represents a hydrogen atom or a hydroxyl protecting group, with a compound of formula **III**



III

in which Z represents a leaving group, or the corresponding isocyanate; or

(b) reducing a compound of formula **IV**



IV

wherein R^e represents a hydrogen atom or a residue of an alcohol;

followed by removing any protecting group and, if desired, forming a pharmaceutically acceptable salt.


3. A pharmaceutical composition, comprising a compound of claim 1 and a pharmaceutically acceptable carrier or diluent.

4. A compound according to claim 1 for use as a medicament.

5. The use of a compound according to claim 1 in the manufacture of a medicament for the treatment of a kinase-mediated condition in a mammal.

6. The use according to claim 5, wherein said kinase-mediated condition is inflammatory disease, autoimmune disease, destructive bone disorder, proliferative disorder, infectious disease, viral disease, or neurodegenerative disease.


7. A compound of formula II



II

or a salt thereof, in which P^1 represents a hydrogen atom or a hydroxyl protecting group.

8. A compound of formula IV



IV

wherein R^e represents a hydrogen atom or a residue of an alcohol.

9. The use of a prodrug of a compound according to claim 1 in the manufacture of a medicament for the treatment with a compound according to claim 1 of a kinase-mediated condition in a mammal., wherein the prodrug is 2-(5-(2-((3-(3-*tert*-butyl-1-*p*-tolyl-1*H*-pyrazol-5-yl)ureido)methyl)-4-fluorophenoxy)-1*H*-indazol-1-yl)ethyl dihydrogenphosphate, or a pharmaceutically acceptable salt thereof.

10. The use according to claim 9, wherein said kinase-mediated condition is inflammatory disease, autoimmune disease, destructive bone disorder, proliferative disorder, infectious disease, viral disease, or neurodegenerative disease.


11. 2-(5-(2-((3-(3-*Tert*-butyl-1-*p*-tolyl-1*H*-pyrazol-5-yl)ureido)methyl)-4-fluorophenoxy)-1*H*-indazol-1-yl)ethyl dihydrogenphosphate, or a pharmaceutically acceptable salt thereof.

12. A pharmaceutical composition, comprising a compound of claim 11 and a pharmaceutically acceptable carrier or diluent.

13. The process according to claim 2, wherein Z is an aryloxy group optionally substituted with one or more groups selected from F, Cl, Br, and NO_2.

14. The process of claim 2, wherein said compound of formula (**II**) has been prepared by the method comprising:

(i) reducing a compound of formula (**V**)



(**V**)

in which P^2 represents hydrogen or a hydroxyl protecting group, under catalytic hydrogenation conditions or in the presence of nickel boride.